Recce’s unapproved drug proves successful treatment for life-threatening illness

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/338262/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/2021/Headlines03_360_210407.jpg’]

Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illness.

Despite not undertaking clinical trials, nasal treatment R327 was accessible to the individual via Category A of the Therapeutic Goods Administration special access scheme. Recce (ASX:RCE) intends to proceed with clinical trials for the product.

The news has shot Recce’s shares up 5.1 per cent to $1.03
Copyright 2021 – Finance News Network

Source: Finance News Network